Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma.

about

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma.

Item

http://www.wikidata.org/entity/Q55383806

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Efficacy and tolerability of b ...... ly diagnosed multiple myeloma.

@en

Efficacy and tolerability of b ...... ly diagnosed multiple myeloma.

@nl

type

Item

label

Efficacy and tolerability of b ...... ly diagnosed multiple myeloma.

@en

Efficacy and tolerability of b ...... ly diagnosed multiple myeloma.

@nl

prefLabel

Efficacy and tolerability of b ...... ly diagnosed multiple myeloma.

@en

Efficacy and tolerability of b ...... ly diagnosed multiple myeloma.

@nl

P1476

Efficacy and tolerability of b ...... ly diagnosed multiple myeloma.

@en

P2093

Afaq Ahmed Khan

http://www.w3.org/2001/XMLSchema#string

Manorama Bhargava

http://www.w3.org/2001/XMLSchema#string

Mir Sadaqat Hassan Zafar

http://www.w3.org/2001/XMLSchema#string

Shyam Aggarwal

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.

Chemotherapy-induced neuropathy.

Front-line treatment in younger patients with multiple myeloma.

Current multiple myeloma treatment strategies with novel agents: a European perspective

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party.

P304

58-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/SAJC.SAJC_59_17

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29600238

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

P932

5865101

http://www.w3.org/2001/XMLSchema#string